Literature DB >> 22568666

Discomfort from an alkaline formulation delivered subcutaneously in humans: albumin at pH 7 versus pH 10.

W Kenneth Ward1, Jessica R Castle, Deborah L Branigan, Ryan G Massoud, Joseph El Youssef.   

Abstract

BACKGROUND AND
OBJECTIVE: There is a paucity of data regarding tolerability of alkaline drugs administered subcutaneously. The aim of this study was to assess the tolerability of alkaline preparations of human albumin delivered subcutaneously to healthy humans.
METHODS: We compared the tolerability of neutral versus alkaline (pH 10) formulations of human albumin in ten volunteers. With an intent to minimize the time required to reach physiological pH after injection, the alkaline formulation was buffered with a low concentration of glycine (20 mmol/L). Each formulation was given at two rates: over 5 seconds and over 60 seconds. A six-point scale was used to assess discomfort.
RESULTS: For slow injections, there was a significant difference between pH 7.4 and pH 10 injections (0.4 ± 0.2 vs 1.1 ± 0.2, mean ± SEM; p = 0.025), though the degree of discomfort at pH 10 injections was only 'mild or slight'. For fast injections, the difference between neutral and alkaline formulations was of borderline significance. Inflammation and oedema, as judged by a physician, were very minimal for all injections, irrespective of pH.
CONCLUSION: For subcutaneous drug administration (especially when delivered slowly), there was more discomfort associated with alkaline versus neutral formulations of albumin, though the discomfort was mild. This study suggests that there is little discomfort and inflammation resulting from subcutaneous administration of protein drugs formulated with weak buffers at alkaline pH.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22568666      PMCID: PMC3683840          DOI: 10.2165/11632840-000000000-00000

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  8 in total

1.  Subcutaneous furosemide.

Authors:  Miguel A Goenaga; Manuel Millet; Eloy Sánchez; Carmen Garde; José A Carrera; Edurne Arzellus
Journal:  Ann Pharmacother       Date:  2004-08-31       Impact factor: 3.154

Review 2.  Current perspectives on pain upon injection of drugs.

Authors:  G A Brazeau; B Cooper; K A Svetic; C L Smith; P Gupta
Journal:  J Pharm Sci       Date:  1998-06       Impact factor: 3.534

3.  In vitro and in vivo evaluation of native glucagon and glucagon analog (MAR-D28) during aging: lack of cytotoxicity and preservation of hyperglycemic effect.

Authors:  W Kenneth Ward; Ryan G Massoud; Cory J Szybala; Julia M Engle; Joseph El Youssef; Julie M Carroll; Charles T Roberts; Richard D DiMarchi
Journal:  J Diabetes Sci Technol       Date:  2010-11-01

4.  A bihormonal closed-loop artificial pancreas for type 1 diabetes.

Authors:  Firas H El-Khatib; Steven J Russell; David M Nathan; Robert G Sutherlin; Edward R Damiano
Journal:  Sci Transl Med       Date:  2010-04-14       Impact factor: 17.956

5.  Local tolerance of subcutaneous injections.

Authors:  J Fransson; A Espander-Jansson
Journal:  J Pharm Pharmacol       Date:  1996-10       Impact factor: 3.765

6.  Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes.

Authors:  Jessica R Castle; Julia M Engle; Joseph El Youssef; Ryan G Massoud; Kevin C J Yuen; Ryland Kagan; W Kenneth Ward
Journal:  Diabetes Care       Date:  2010-03-23       Impact factor: 17.152

7.  Pain on i.v. injection of some anaesthetic agents is evoked by the unphysiological osmolality or pH of their formulations.

Authors:  W Klement; J O Arndt
Journal:  Br J Anaesth       Date:  1991-02       Impact factor: 9.166

8.  Diuretic effects of subcutaneous furosemide in human volunteers: a randomized pilot study.

Authors:  Arun K Verma; Jack H da Silva; David R Kuhl
Journal:  Ann Pharmacother       Date:  2004-02-24       Impact factor: 3.154

  8 in total
  4 in total

Review 1.  Stable liquid glucagon formulations for rescue treatment and bi-hormonal closed-loop pancreas.

Authors:  Melanie A Jackson; Nicholas Caputo; Jessica R Castle; Larry L David; Charles T Roberts; W Kenneth Ward
Journal:  Curr Diab Rep       Date:  2012-12       Impact factor: 4.810

2.  Mechanisms of glucagon degradation at alkaline pH.

Authors:  Nicholas Caputo; Jessica R Castle; Colin P Bergstrom; Julie M Carroll; Parkash A Bakhtiani; Melanie A Jackson; Charles T Roberts; Larry L David; W Kenneth Ward
Journal:  Peptides       Date:  2013-05-04       Impact factor: 3.750

3.  Biochemical stabilization of glucagon at alkaline pH.

Authors:  Nicholas Caputo; Melanie A Jackson; Jessica R Castle; Joseph El Youssef; Parkash A Bakhtiani; Colin P Bergstrom; Julie M Carroll; Matthew E Breen; Gerald L Leonard; Larry L David; Charles T Roberts; W Kenneth Ward
Journal:  Diabetes Technol Ther       Date:  2014-06-26       Impact factor: 6.118

Review 4.  New insight into the importance of formulation variables on parenteral growth hormone preparations: potential effect on the injection-site pain.

Authors:  Bita Taghizadeh; Mahmoud Reza Jaafari; Nosratollah Zarghami
Journal:  Front Endocrinol (Lausanne)       Date:  2022-10-03       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.